

META HEALTH LIMITED
(Company Registration No. 198804700N)
(Incorporated in the Republic of Singapore)

USE OF PROCEEDS FROM THE RIGHTS ISSUE

1. INTRODUCTION

- 1.1 The board of directors (the “**Board**” or “**Directors**”) of Meta Health Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the Company’s offer information statement dated and electronically disseminated on 22 January 2025 (“**Offer Information Statement**”) in relation to the renounceable non-underwritten rights issue (“**Rights Issue**”) which had been lodged with the Singapore Exchange Securities Trading Limited, acting as agent on behalf of the Monetary Authority of Singapore, and the Company’s announcement dated 12 February 2025 in relation to the results of the Rights Issue (“**12 February 2025 Announcement**”).
- 1.2 Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meaning as ascribed to them in the Offer Information Statement.

2. USE OF PROCEEDS FROM THE RIGHTS ISSUE

- 2.1 The Board wishes to update that the Net Proceeds of approximately S\$1.43 million from the Rights Issue have been fully utilised. The following table summarises the use of the Net Proceeds:

Use of Net Proceeds	Net Proceeds as disclosed in the 12 February 2025 Announcement (\$’000)	Amount utilised from the 12 February 2025 Announcement up to 15 May 2025^(a) (\$’000)	Amount utilised from 16 May 2025 up to the date of this announcement (\$’000)	Balance of Net Proceeds as at the date of this announcement (\$’000)
Repayment of existing loans	790	(540) ^{(b)(c)}	(250) ^(b)	-
General corporate and working capital purposes of the Group	640	(640) ^(d)	-	-
Total	1,430	(1,180)	(250)	-

Notes:

- (a) As reported in the Company’s announcement dated 15 May 2025, in relation to the Group’s unaudited financial results for the first quarter ended 31 March 2025.
- (b) Relates to repayment of the term loan of a principal sum of S\$0.64 million provided by United Overseas Bank Limited to the Company, which matured in July 2025, as disclosed in paragraph 6 of Part 4 of the Offer Information Statement.

- (c) Relates to repayment of the term loan of a principal sum of S\$0.15 million provided by MWA Capital Pte Ltd to the Company, which matured in March 2025, as disclosed in paragraph 6 of Part 4 of the Offer Information Statement
- (d) The breakdown of the use of Net Proceeds for general working capital purposes of the Group is as follows:

	S\$ '000
Employee benefit expenses	26
Corporate expenses, rental, and legal & professional fees	614
Total	<u>640</u>

2.2 The use of the Net Proceeds is in accordance with the intended uses and allocations as disclosed in the Offer Information Statement and the 12 February 2025 Announcement.

BY ORDER OF THE BOARD

Gwendolin Lee Soo Fern
Company Secretary

05 August 2025

This announcement has been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "**Sponsor**").

This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lim Hui Zheng, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.